Research programme: acid-sensing ion channels inhibitors - Neurasic Therapeutics
Latest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator McGill University
- Developer McGill University; Neurasic Therapeutics
- Class Analgesics
- Mechanism of Action ASIC channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Pain in USA
- 05 Jun 2020 Early research in Pain in USA (unspecified route)